{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:42:32Z","timestamp":1793263352745,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008700","name":"Centre International de Recherche sur le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"EC | Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The US National Cancer Centre for Global Health European Society of Gynaecology Oncology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2024,3,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cervical carcinogenesis is mediated by the HPV-E6 and E7 oncoproteins, considered as biomarkers usable in managing screen-positive women.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a systematic review and meta-analysis assessing the accuracy of HPV-E6\/E7-oncoprotein tests to detect underlying cervical-precancer and cancer. We included studies reporting data on oncoprotein test accuracy detecting cervical intraepithelial neoplasia grade 3 or worse. Random effects logistic regression models were applied for pooling absolute and relative accuracy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty-two studies were included. Sensitivity and specificity estimates ranged from 54.2% (95%CI: 45.2\u201363.0) to 69.5% (95%CI:60.8\u201376.9) and from 82.8% (95%CI: 50.4\u201395.8) to 99.1 (95%CI: 98.8\u201399.3), respectively in the population irrespective of HPV status. Higher sensitivity estimates ranging from 60.8% (95%CI: 49.6\u201370.9) to 75.5% (95%CI: 71.7\u201378.9) but lower specificity estimates ranging from 83.7% (95%CI: 76.1\u201389.3) to 92.1% (95%CI: 88.5\u201394.6) were observed in studies enrolling high-risk-HPV-positive women. Studies recruiting only HIV-positive women showed a pooled sensitivity of 46.9% (95%CI: 30.6\u201363.9) with a specificity of 98.0% (95%CI: 96.8\u201398.7).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The high specificity of oncoprotein tests supports its use for triaging HPV-positive women. However, oncoprotein-negative women would not be recommended to undertake routine screening, requiring further follow-up. Large-scale and longitudinal studies are needed to further investigate the role of E6\/E7-oncoprotein detection in predicting the risk of developing cervical pre-cancer and cancer.<\/jats:p>\n                \n              <\/jats:sec>","DOI":"10.1038\/s41416-023-02490-w","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T17:02:42Z","timestamp":1700154162000},"page":"517-525","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Accuracy of HPV E6\/E7 oncoprotein tests to detect high-grade cervical lesions: a systematic literature review and meta-analysis"],"prefix":"10.1038","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1669-6298","authenticated-orcid":false,"given":"Laura","family":"Downham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Jaafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Luz","family":"Rol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Nyawira Nyaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Valls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Baena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc J.","family":"Gunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7807-5908","authenticated-orcid":false,"given":"Marc","family":"Arbyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maribel","family":"Almonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"key":"2490_CR1","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1016\/S2214-109X(22)00501-0","volume":"11","author":"D Singh","year":"2023","unstructured":"Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 2023;11:e197\u2013e206.","journal-title":"Lancet Glob Health"},{"key":"2490_CR2","unstructured":"Cancer Today GCO. Estimated number of new cases in 2020, worldwide, females, all ages 2020 [Available from: https:\/\/gco.iarc.fr\/today\/online-analysis-table?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=asr&sex=2&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&group_cancer=1&include_nmsc=0&include_nmsc_other=1. Access Date: March 3, 2022."},{"key":"2490_CR3","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1080\/01443615.2019.1634030","volume":"40","author":"KS Okunade","year":"2020","unstructured":"Okunade KS. Human papillomavirus and cervical cancer. J Obstet Gynaecol. 2020;40:602\u20138.","journal-title":"J Obstet Gynaecol"},{"key":"2490_CR4","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1093\/jnci\/djn044","volume":"100","author":"AC Rodr\u00edguez","year":"2008","unstructured":"Rodr\u00edguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst. 2008;100:513\u20137.","journal-title":"J Natl Cancer Inst"},{"key":"2490_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta13510","volume":"13","author":"HC Kitchener","year":"2009","unstructured":"Kitchener HC, Almonte M, Gilham C, Dowie R, Stoykova B, Sargent A, et al. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess. 2009;13:1\u2013150.","journal-title":"Health Technol Assess"},{"key":"2490_CR6","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1086\/516784","volume":"195","author":"M Plummer","year":"2007","unstructured":"Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis. 2007;195:1582\u20139.","journal-title":"J Infect Dis"},{"key":"2490_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/jnci\/djq001","volume":"102","author":"AC Rodr\u00edguez","year":"2010","unstructured":"Rodr\u00edguez AC, Schiffman M, Herrero R, Hildesheim A, Bratti C, Sherman ME, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2\/3: critical role of duration of infection. J Natl Cancer Inst. 2010;102:315\u201324.","journal-title":"J Natl Cancer Inst"},{"key":"2490_CR8","unstructured":"World Health Organization. New recommendations for screening and treatment to prevent cervical cancer 2021 [Available from: https:\/\/www.who.int\/news\/item\/06-07-2021-new-recommendations-for-screening-and-treatment-to-prevent-cervical-cancer. Access Date: March 3, 2022."},{"key":"2490_CR9","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.cmi.2015.04.015","volume":"21","author":"M Arbyn","year":"2015","unstructured":"Arbyn M, Snijders PJ, Meijer CJ, Berkhof J, Cuschieri K, Kocjan BJ, et al. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? Clin Microbiol Infect. 2015;21:817\u201326.","journal-title":"Clin Microbiol Infect"},{"key":"2490_CR10","doi-asserted-by":"publisher","first-page":"F88","DOI":"10.1016\/j.vaccine.2012.06.095","volume":"30","author":"M Arbyn","year":"2012","unstructured":"Arbyn M, Ronco G, Anttila A M, Meijer CJ, Poljak M, Ogilvie G, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30:F88\u2013F99.","journal-title":"Vaccine"},{"key":"2490_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31\u201346.","journal-title":"Cancer Discov"},{"key":"2490_CR12","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.chom.2014.02.011","volume":"15","author":"EA Mesri","year":"2014","unstructured":"Mesri EA, Feitelson MA, Munger K. Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe. 2014;15:266\u201382.","journal-title":"Cell Host Microbe"},{"key":"2490_CR13","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.biopha.2018.06.149","volume":"106","author":"RP Araldi","year":"2018","unstructured":"Araldi RP, Sant\u2019Ana TA, M\u00f3dolo DG, de Melo TC, Spadacci-Morena DD, de Cassia Stocco R, et al. The human papillomavirus (HPV)-related cancer biology: an overview. Biomed Pharmacother. 2018;106:1537\u201356.","journal-title":"Biomed Pharmacother"},{"key":"2490_CR14","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1093\/carcin\/bgp333","volume":"31","author":"E Boccardo","year":"2010","unstructured":"Boccardo E, Baldi CVM, Carvalho AF, Rabachini T, Torres C, Barreta LA, et al. Expression of human papillomavirus type 16 E7 oncoprotein alters keratinocytes expression profile in response to tumor necrosis factor-alpha. Carcinogenesis. 2010;31:521\u201331.","journal-title":"Carcinogenesis"},{"key":"2490_CR15","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrc2886","volume":"10","author":"CA Moody","year":"2010","unstructured":"Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10:550\u201360.","journal-title":"Nat Rev Cancer"},{"key":"2490_CR16","doi-asserted-by":"publisher","first-page":"4705","DOI":"10.1128\/JVI.75.10.4705-4712.2001","volume":"75","author":"M Giarr\u00e8","year":"2001","unstructured":"Giarr\u00e8 M, Caldeira S, Malanchi I, Ciccolini F, Le\u00e3o MJ, Tommasino M. Induction of pRb degradation by the human papillomavirus type 16 E7 protein is essential to efficiently overcome p16INK4a-imposed G1 cell cycle Arrest. J Virol. 2001;75:4705\u201312.","journal-title":"J Virol"},{"key":"2490_CR17","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.3390\/ijms19061706","volume":"19","author":"NSL Yeo-Teh","year":"2018","unstructured":"Yeo-Teh NSL, Ito Y, Jha S. High-risk human papillomaviral oncogenes E6 and E7 target key cellular pathways to achieve oncogenesis. Int J Mol Sci. 2018;19:1706.","journal-title":"Int J Mol Sci"},{"key":"2490_CR18","doi-asserted-by":"publisher","first-page":"e1006211","DOI":"10.1371\/journal.ppat.1006211","volume":"13","author":"AA McBride","year":"2017","unstructured":"McBride AA, Warburton A. The role of integration in oncogenic progression of HPV-associated cancers. PLoS Pathog. 2017;13:e1006211.","journal-title":"PLoS Pathog"},{"key":"2490_CR19","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.cmi.2021.04.031","volume":"27","author":"M Arbyn","year":"2021","unstructured":"Arbyn M, Simon M, Peeters E, Xu L, Meijer C, Berkhof J, et al. 2020 list of human papillomavirus assays suitable for primary cervical cancer screening. Clin Microbiol Infect. 2021;27:1083\u201395.","journal-title":"Clin Microbiol Infect"},{"key":"2490_CR20","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Bmj. 2009;339:b2700.","journal-title":"Bmj"},{"key":"2490_CR21","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj. 2021;372:n71.","journal-title":"Bmj"},{"key":"2490_CR22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3163\/1536-5050.103.4.004","volume":"103","author":"Y Kwon","year":"2015","unstructured":"Kwon Y, Lemieux M, McTavish J, Wathen N. Identifying and removing duplicate records from systematic review searches. J Med Libr Assoc. 2015;103:184\u20138.","journal-title":"J Med Libr Assoc"},{"key":"2490_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.","journal-title":"Syst Rev"},{"key":"2490_CR24","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","volume":"155","author":"PF Whiting","year":"2011","unstructured":"Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529\u201336.","journal-title":"Ann Intern Med"},{"key":"2490_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13690-021-00747-5","volume":"80","author":"VN Nyaga","year":"2022","unstructured":"Nyaga VN, Arbyn M. Metadta: a Stata command for meta-analysis and meta-regression of diagnostic test accuracy data\u2014a tutorial. Arch Public Health. 2022;80:95.","journal-title":"Arch Public Health"},{"key":"2490_CR26","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.ygyno.2020.06.496","volume":"158","author":"R Ara","year":"2020","unstructured":"Ara R, Khatun S, Pervin S, Jahan M, Shahera U, Ferdous J, et al. Role of molecular biomarker human papilloma virus (HPV) E6 oncoprotein in cervical cancer screening. Gynecol Oncol. 2020;158:590\u20136.","journal-title":"Gynecol Oncol"},{"key":"2490_CR27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/ijc.30761","volume":"141","author":"T Agorastos","year":"2017","unstructured":"Agorastos T, Chatzistamatiou K, Moysiadis T, Kaufmann AM, Skenderi A, Lekka I, et al. Human papillomavirus E7 protein detection as a method of triage to colposcopy of HPV positive women, in comparison to genotyping and cytology. Final results of the PIPAVIR study. Int J Cancer. 2017;141:519\u201330.","journal-title":"Int J Cancer"},{"key":"2490_CR28","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/LGT.0000000000000206","volume":"20","author":"CJ Chibwesha","year":"2016","unstructured":"Chibwesha CJ, Frett B, Katundu K, Bateman AC, Shibemba A, Kapambwe S, et al. Clinical performance validation of 4 point-of-care cervical cancer screening tests in HIV-infected women in Zambia. J Low Genit Trac Dis. 2016;20:218\u201323.","journal-title":"J Low Genit Trac Dis"},{"key":"2490_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jcv.2016.06.015","volume":"82","author":"J Cuzick","year":"2016","unstructured":"Cuzick J, Ahmad AS, Austin J, Cadman L, Ho L, Terry G, et al. A comparison of different human papillomavirus tests in PreservCyt versus SurePath in a referral population-PREDICTORS 4. J Clin Virol. 2016;82:145\u201351.","journal-title":"J Clin Virol"},{"key":"2490_CR30","doi-asserted-by":"publisher","first-page":"e0232105","DOI":"10.1371\/journal.pone.0232105","volume":"15","author":"CM de Oliveira","year":"2020","unstructured":"de Oliveira CM, Musselwhite LW, Pantano ND, Vazquez FL, Smith JS, Schweizer J, et al. Detection of HPV E6 oncoprotein from urine via a novel immunochromatographic assay. Plos One. 2020;15:e0232105.","journal-title":"Plos One"},{"key":"2490_CR31","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1002\/ijc.32156","volume":"145","author":"A Ferrera","year":"2019","unstructured":"Ferrera A, Valladares W, Cabrera Y, de la Luz Hernandez M, Darragh T, Baena A, et al. Performance of an HPV 16\/18 E6 oncoprotein test for detection of cervical precancer and cancer. Int J Cancer. 2019;145:2042\u201350.","journal-title":"Int J Cancer"},{"key":"2490_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07483-z","volume":"20","author":"L Kong","year":"2020","unstructured":"Kong L, Xiao X, Lou H, Liu P, Song S, Liu M, et al. Analysis of the role of the human papillomavirus 16\/18 E7 protein assay in screening for cervical intraepithelial neoplasia: a case control study. BMC Cancer. 2020;20:999.","journal-title":"BMC Cancer"},{"key":"2490_CR33","doi-asserted-by":"publisher","first-page":"e0164892","DOI":"10.1371\/journal.pone.0164892","volume":"11","author":"VS Mariano","year":"2016","unstructured":"Mariano VS, Lorenzi AT, Scapulatempo C, Stein MD, Resende JCP, Antoniazzi M, et al. A low-cost HPV immunochromatographic assay to detect high-grade cervical intraepithelial neoplasia. Plos One. 2016;11:e0164892.","journal-title":"Plos One"},{"key":"2490_CR34","doi-asserted-by":"publisher","first-page":"e029088","DOI":"10.1136\/bmjopen-2019-029088","volume":"9","author":"Z Ndizeye","year":"2019","unstructured":"Ndizeye Z, Menon S, Van Geertruyden J-P, Sauvaget C, Jacquemyn Y, Bogers J-P, et al. Performance of OncoE6 (TM) Cervical Test in detecting cervical precancer lesions in HIV-positive women attending an HIV clinic in Bujumbura, Burundi: a cross-sectional study. Bmj Open. 2019;9:e029088.","journal-title":"Bmj Open"},{"key":"2490_CR35","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1002\/ijc.28616","volume":"134","author":"YL Qiao","year":"2014","unstructured":"Qiao YL, Jeronimo J, Zhao FH, Schweizer J, Chen W, Valdez M, et al. Lower cost strategies for triage of human papillomavirus DNA-positive women. Int J Cancer. 2014;134:2891\u2013901.","journal-title":"Int J Cancer"},{"key":"2490_CR36","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/ijc.31633","volume":"144","author":"R Rezhake","year":"2019","unstructured":"Rezhake R, Hu SY, Zhao S, Xu XQ, Zhao XL, Zhang L, et al. Eight-type human papillomavirus E6\/E7 oncoprotein detection as a novel and promising triage strategy for managing HPV-positive women. Int J Cancer. 2019;144:34\u201342.","journal-title":"Int J Cancer"},{"key":"2490_CR37","doi-asserted-by":"publisher","first-page":"4646","DOI":"10.1128\/JCM.01315-10","volume":"48","author":"J Schweizer","year":"2010","unstructured":"Schweizer J, Lu PS, Mahoney CW, Berard-Bergery M, Ho M, Ramasamy V, et al. Feasibility study of a human papillomavirus E6 oncoprotein test for diagnosis of cervical precancer and cancer. J Clin Microbiol. 2010;48:4646\u20138.","journal-title":"J Clin Microbiol"},{"key":"2490_CR38","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/LGT.0b013e3181f6c84d","volume":"15","author":"JW Sellors","year":"2011","unstructured":"Sellors JW, Schweizer JG, Lu PS, Liu B, Weigl BH, Cui JF, et al. Association of elevated E6 oncoprotein with grade of cervical neoplasia using PDZ interaction-mediated precipitation of E6. J Low Genit Trac Dis. 2011;15:169\u201376.","journal-title":"J Low Genit Trac Dis"},{"key":"2490_CR39","first-page":"6251","volume":"14","author":"WJ Shi","year":"2017","unstructured":"Shi WJ, Liu H, Wu D, Tang ZH, Shen YC, Guo L. E6\/E7 proteins are potential markers for the screening and diagnosis of cervical pre-cancerous lesions and cervical cancer in a Chinese population. Oncol Lett. 2017;14:6251\u20138.","journal-title":"Oncol Lett"},{"key":"2490_CR40","doi-asserted-by":"publisher","first-page":"e0201262","DOI":"10.1371\/journal.pone.0201262","volume":"13","author":"KL Torres","year":"2018","unstructured":"Torres KL, Mari\u00f1o JM, Pires Rocha DA, de Mello MB, de Melo Farah HH, Reis RDS, et al. Self-sampling coupled to the detection of HPV 16 and 18 E6 protein: A promising option for detection of cervical malignancies in remote areas. PLoS One. 2018;13:e0201262.","journal-title":"PLoS One"},{"key":"2490_CR41","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1002\/ijc.33414","volume":"148","author":"L Torres-Ibarra","year":"2021","unstructured":"Torres-Ibarra L, Lorincz AT, Wheeler CM, Cuzick J, Hern\u00e1ndez-L\u00f3pez R, Spiegelman D, et al. Adjunctive testing by cytology, p16\/Ki-67 dual-stained cytology or HPV16\/18 E6 oncoprotein for the management of HPV16\/18 screen-positive women. Int J Cancer. 2021;148:2264\u201373.","journal-title":"Int J Cancer"},{"key":"2490_CR42","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1002\/ijc.29877","volume":"138","author":"M Valdez","year":"2016","unstructured":"Valdez M, Jeronimo J, Bansil P, Qiao YL, Zhao FH, Chen W, et al. Effectiveness of novel, lower cost molecular human papillomavirus-based tests for cervical cancer screening in rural China. Int J Cancer. 2016;138:1453\u201361.","journal-title":"Int J Cancer"},{"key":"2490_CR43","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jcv.2018.08.008","volume":"108","author":"ZN Wu","year":"2018","unstructured":"Wu ZN, Yu LL, Lei XQ, Qin Y, Zhang X, Chen W, et al. The association between human papillomavirus 16, 18 DNA load and E6 protein expression in cervical intraepithelial neoplasia and cancer. J Clin Virol. 2018;108:6\u201311.","journal-title":"J Clin Virol"},{"key":"2490_CR44","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1128\/CVI.00388-12","volume":"19","author":"YS Yang","year":"2012","unstructured":"Yang YS, Smith-McCune K, Darragh TM, Lai Y, Lin JH, Chang TC, et al. Direct human papillomavirus E6 whole-cell enzyme-linked immunosorbent assay for objective measurement of E6 oncoproteins in cytology samples. Clin Vaccin Immunol. 2012;19:1474\u20139.","journal-title":"Clin Vaccin Immunol"},{"key":"2490_CR45","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/ijc.31368","volume":"143","author":"LL Yu","year":"2018","unstructured":"Yu LL, Jiang MY, Qu PP, Wu ZN, Sun PS, Xi MR, et al. Clinical evaluation of human papillomavirus 16\/18 oncoprotein test for cervical cancer screening and HPV positive women triage. Int J Cancer. 2018;143:813\u201322.","journal-title":"Int J Cancer"},{"key":"2490_CR46","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/ijc.30807","volume":"141","author":"Q Zhang","year":"2017","unstructured":"Zhang Q, Dong L, Hu S, Feng R, Zhang X, Pan Q, et al. Risk stratification and long-term risk prediction of E6 oncoprotein in a prospective screening cohort in China. Int J Cancer. 2017;141:1110\u20139.","journal-title":"Int J Cancer"},{"key":"2490_CR47","first-page":"164","volume":"29","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Sun L, Zhao H, Zhang Y, Wang L, Ma Z, et al. Application of human papillomavirus 16\/18 E6 protein detection for cervical cancer screening. Cancer Res Clin. 2017;29:164\u20137.","journal-title":"Cancer Res Clin"},{"key":"2490_CR48","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1158\/1940-6207.CAPR-13-0091","volume":"6","author":"FH Zhao","year":"2013","unstructured":"Zhao FH, Jeronimo J, Qiao YL, Schweizer J, Chen W, Valdez M, et al. An evaluation of novel, lower-cost molecular screening tests for human papillomavirus in rural China. Cancer Prev Res. 2013;6:938\u201348.","journal-title":"Cancer Prev Res"},{"key":"2490_CR49","first-page":"531","volume":"139","author":"S Shukla","year":"2014","unstructured":"Shukla S, Mahata S, Shishodia G, Pande S, Verma G, Hedau S, et al. Physical state & copy number of high risk human papillomavirus type 16 DNA in progression of cervical cancer. Indian J Med Res. 2014;139:531\u201343.","journal-title":"Indian J Med Res"},{"key":"2490_CR50","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543:378\u201384.","DOI":"10.1038\/nature21386"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-023-02490-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-023-02490-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-023-02490-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T18:08:23Z","timestamp":1708366103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-023-02490-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,3,9]]}},"alternative-id":["2490"],"URL":"https:\/\/doi.org\/10.1038\/s41416-023-02490-w","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,16]]},"assertion":[{"value":"15 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}